A key Trump administration agency is drawing controversy over policies that might slow the process for bringing lower-cost medicines to market. Over the past year, the U.S. Patent & Trademark Office (PTO) has taken several steps that were billed as preserving patents from unnecessary legal challenges and strengthening the system for protecting innovation.